Adaptin Bio (APTN) Cash & Equivalents (2022 - 2026)

Adaptin Bio has disclosed Cash & Equivalents across 5 years of filings, most recently posting $301309.0 for Q1 2026.

• Quarterly Cash & Equivalents fell 87.31% year-over-year to $301309.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $301309.0 (down 87.31% YoY) and the FY2025 annual result came in at $459174.0, up 1247.14% from the prior year.
• Cash & Equivalents slipped to $301309.0 in Q1 2026, from $459174.0 in the prior quarter.
• Across five years, Cash & Equivalents topped out at $2.4 million in Q1 2025 and bottomed at $322.0 in Q3 2024.
• The 5-year median for Cash & Equivalents is $23776.0 (2024), against an average of $394976.6.
• Year-over-year, Cash & Equivalents surged 179741.3% in 2025 and slumped 87.31% in 2026.
• Adaptin Bio's Cash & Equivalents stood at $500.0 in 2022, then jumped by 850.8% to $4754.0 in 2023, then surged by 616.98% to $34085.0 in 2024, then soared by 1247.14% to $459174.0 in 2025, then tumbled by 34.38% to $301309.0 in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $301309.0, $459174.0, and $579089.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.